Table 1.
Baseline participant characteristics by randomized groups
| TDF/FTC (n = 30) | Standard of Care (n = 30) | |
|---|---|---|
| Mean Age (SD), year, mean (SD) | 39.9 (14.8) | 42.6 (16.7) |
| Women | 16 (53%) | 18 (60%) |
| Body-mass index, kg/m2 | 24.9 (3.7) | 23.7 (3.7) |
| Health care worker | 17 (57%) | 18 (60%) |
| Smoker | 8 (27%) | 10 (33%) |
| Comorbid condition | ||
| Hypertension | 2 (7%) | 1 (3%) |
| Diabetes | 1 (3%) | 1 (3%) |
| Moderate COVID-19 (vs mild) | 1 (3%) | 2 (6%) |
| Duration of prior symptoms, median [IQR] | 4 [3-5] | 4 [3-5] |
| 2 or <2 d | 6 (20%) | 7 (23%) |
| 3-4 d | 14 (47%) | 15 (50%) |
| >4 d | 10 (33%) | 8 (27%) |
| Symptoms at baseline | 30 (100%) | 30 (100%) |
| Olfactory loss | 15 (50%) | 12 (40%) |
| Gustatory loss | 15 (50%) | 10 (33%) |
| Fatigue | 20 (67%) | 24 (80%) |
| Cough | 16 (53%) | 18 (60%) |
| Headache | 17 (57%) | 16 (53%) |
| Shortness of breath | 11 (37%) | 9 (30%) |
| Nausea | 5 (17%) | 8 (27%) |
| Rhinitis | 14 (47%) | 20 (67%) |
| Number of symptoms at baseline, median [IQR] | 5 [3–8] | 5 [4–6] |
| Vital signs | ||
| Respiratory frequency, cycle/min | 17.8 (2.7) | 17.1 (2.6) |
| Oxymetry, (%) | 98.7 (1.3) | 98.8 (1.2) |
| Temperature,°C | 36.8 (0.9) | 36.7 (0.8) |
| Heart rate, beat/min | 77 (15) | 80 (13) |
| Laboratory measures | ||
| SARS-CoV-2 Ct RT-PCR per swab, mean (SD) | 21.0 (5.3) | 23.5 (5.5) |
| e-GFR, mL/min, mean (SD) | 122 (30) | 111 (31) |
| C-reactive protein, mg/L, mean (SD)* | 6.8 (8.8) | 6.4 (8.2) |
| <5 mg/L | 18 (60%) | 22 (73%) |
| 5 to 10 mg/mL | 8 (27%) | 3 (10%) |
| >10 mg/mL | 4 (13%) | 5 (17%) |
*Data missing for 2 patients; TDF/FTC, tenofovir disoproxil fumarate and emtricitabine; IQR, interquartile range; SD, Standard deviation.
None of the differences between groups was statistically significant.